6-[F-18]Fluoro-<scp>l</scp>-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine ExcessHelle‐Brit Fiebrich, Thera P. Links, Adrienne H. Brouwers et al.|The Journal of Clinical Endocrinology & Metabolism|2009Cited by 155
<sup>89</sup>Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic TreatmentSjoukje F. Oosting, Elisabeth G.E. de Vries, Adrienne H. Brouwers et al.|Journal of Nuclear Medicine|2014Cited by 114
Targeted optical fluorescence imaging: a meta-narrative review and future perspectivesHugo M. Schouw, Schelto Kruijff, Riemer H. J. A. Slart et al.|European Journal of Nuclear Medicine and Molecular Imaging|2021Cited by 81
In Vivo Biodistribution of No-Carrier-Added 6-<sup>18</sup>F-Fluoro-3,4-Dihydroxy-l-Phenylalanine (<sup>18</sup>F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added <sup>18</sup>F-DOPA, Prepared by Conventional Electrophilic SubstitutionWillem-Jan Kuik, Philip H. Elsinga, Ido P. Kema et al.|Journal of Nuclear Medicine|2014Cited by 66
VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patientsWouter B. Nagengast, Geke A.P. Hospers, Marjolijn N. Lub–de Hooge et al.|European Journal of Cancer|2011Cited by 55